ONO 4817

Drug Profile

ONO 4817

Latest Information Update: 23 Jun 2005

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Phenyl ethers; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Endometriosis; Inflammatory bowel diseases; Osteoarthritis

Most Recent Events

  • 18 May 2005 Discontinued - Phase-I for Osteoarthritis in Japan (PO)
  • 18 May 2005 Discontinued - Phase-I for Inflammatory bowel disease in United Kingdom (PO)
  • 18 May 2005 Discontinued - Phase-I for Inflammatory bowel disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top